Torcetrapib

From Anvita Health Wiki

Jump to: navigation, search

Contents

Indications

Dosage

Adverse-effects

Laboratory

Mechanism-of-action

More General Terms

Internet Database

PubChem: 159325

References

  1. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004 Apr 8;350(15):1505-15. PMID: [1]
  2. Brewer HB Jr. Increasing HDL Cholesterol Levels. N Engl J Med. 2004 Apr 8;350(15):1491-4. No abstract available. PMID: [2]
  3. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):490-7. Epub 2004 Jan 22. PMID: [3]
  4. Bays H, Stein EA. Pharmacotherapy for dyslipidaemia--current therapies and future agents. Expert Opin Pharmacother. 2003 Nov;4(11):1901-38. Review. PMID: [4]
  5. Prescriber's Letter 11(5):27 2004 Detail-Document#: [5] (subscription needed) [6]
  6. Barter PJ et al, Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109 PMID: [7]